메뉴 건너뛰기




Volumn 11, Issue 5, 2010, Pages 409-417

Cost-effectiveness model of empiric doripenem compared with imipenem-cilastatin in ventilator-associated pneumonia

Author keywords

[No Author keywords available]

Indexed keywords

CILASTATIN PLUS IMIPENEM; DORIPENEM;

EID: 77957566204     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2009.076     Document Type: Article
Times cited : (8)

References (29)
  • 1
    • 13644269309 scopus 로고    scopus 로고
    • Hospital-Acquired Pneumonia Guideline Committee of the American Thoracic Society and Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired pneumonia, ventilator-associated pneumonia, and healthcare-associated pneumonia
    • Hospital-Acquired Pneumonia Guideline Committee of the American Thoracic Society and Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired pneumonia, ventilator-associated pneumonia, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
    • (2005) Am. J. Respir Crit. Care Med. , vol.171 , pp. 388-416
  • 2
    • 0032531113 scopus 로고    scopus 로고
    • Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients
    • Cook DJ, Walter SD, Cook RJ, et al. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med 1998;129:433-440.
    • (1998) Ann. Intern. Med. , vol.129 , pp. 433-440
    • Cook, D.J.1    Walter, S.D.2    Cook, R.J.3
  • 3
    • 34047261095 scopus 로고    scopus 로고
    • Estimating health care-associated infections and deaths in U. S. hospitals, 2002
    • Klevens RM, Edwards JR, Richards CL Jr, et al. Estimating health care-associated infections and deaths in U. S. hospitals, 2002. Public Health Rep 2007;122:160-166.
    • (2007) Public Health Rep. , vol.122 , pp. 160-166
    • Klevens, R.M.1    Edwards, J.R.2    Richards Jr., C.L.3
  • 4
    • 0346753421 scopus 로고    scopus 로고
    • National Nosocomial Infections Surveillance (NNIS)
    • National Nosocomial Infections Surveillance System, System Report, data summary from January 1992 through June 2003; issued August 2003
    • National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003; issued August 2003. Am J Infect Control 2003;31:481-498.
    • (2003) Am. J. Infect. Control , vol.31 , pp. 481-498
  • 5
    • 26444480583 scopus 로고    scopus 로고
    • Clinical and economic consequences of ventilator-associated pneumonia: A systematic review
    • Safdar N, Dezfulian C, Collard HR, et al. Clinical and economic consequences of ventilator-associated pneumonia: A systematic review. Crit Care Med 2005;33:2184-2193.
    • (2005) Crit. Care Med. , vol.33 , pp. 2184-2193
    • Safdar, N.1    Dezfulian, C.2    Collard, H.R.3
  • 6
    • 0038662785 scopus 로고    scopus 로고
    • Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center
    • Warren DK, Shukla SJ, Olsen MA, et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003;31:1312-1317.
    • (2003) Crit. Care Med. , vol.31 , pp. 1312-1317
    • Warren, D.K.1    Shukla, S.J.2    Olsen, M.A.3
  • 8
    • 9344239309 scopus 로고    scopus 로고
    • Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit
    • ICU-acquired Pneumonia Study Group
    • Alvarez-Lerma F, ICU-acquired Pneumonia Study Group. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med 1996;22:387-394.
    • (1996) Intensive Care Med. , vol.22 , pp. 387-394
    • Alvarez-Lerma, F.1
  • 9
    • 0036304245 scopus 로고    scopus 로고
    • Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia
    • Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002;122:262-268.
    • (2002) Chest , vol.122 , pp. 262-268
    • Iregui, M.1    Ward, S.2    Sherman, G.3
  • 10
    • 77957608917 scopus 로고    scopus 로고
    • Unpublished data on file. Ortho-McNeil Janssen Scientific Affairs, Raritan, NJ
    • Unpublished data on file. Ortho-McNeil Janssen Scientific Affairs, Raritan, NJ.
  • 11
    • 41649099025 scopus 로고    scopus 로고
    • Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study
    • Chastre J, Wunderink R, Prokocimer P, et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study. Crit Care Med 2008:36; 1089-1096.
    • (2008) Crit. Care Med. , vol.36 , pp. 1089-1096
    • Chastre, J.1    Wunderink, R.2    Prokocimer, P.3
  • 12
    • 77957580747 scopus 로고    scopus 로고
    • Susceptibility of Pseudomonas aeruginosa to doripenem and imipenem in the United States: 2006-2007 TRUST surveillance
    • Poster presentation at, Honolulu, HI, February 2-6
    • Brown N, Draghi DH, Yee YC, et al. Susceptibility of Pseudomonas aeruginosa to doripenem and imipenem in the United States: 2006-2007 TRUST surveillance. Poster presentation at the 37th Critical Care Congress. Honolulu, HI, February 2-6, 2008.
    • (2008) The 37th Critical Care Congress
    • Brown, N.1    Draghi, D.H.2    Yee, Y.C.3
  • 13
    • 0029794708 scopus 로고    scopus 로고
    • Recommendations of the panel on cost-effectiveness in health and medicine
    • Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-1258.
    • (1996) JAMA , vol.276 , pp. 1253-1258
    • Weinstein, M.C.1    Siegel, J.E.2    Gold, M.R.3
  • 14
    • 0029863296 scopus 로고    scopus 로고
    • Ventilator-associated pneumonia due to Pseudomonas aeruginosa
    • Crouch Brewer S, Wunderink RG, Jones CB, Leeper KV. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 1996;109:1019-1029.
    • (1996) Chest , vol.109 , pp. 1019-1029
    • Brewer, S.C.1    Wunderink, R.G.2    Jones, C.B.3    Leeper, K.V.4
  • 15
    • 33749028483 scopus 로고    scopus 로고
    • Imipenem resistance among Pseudomonas aeruginosa isolates: Risk factors for infection and impact of resistance on clinical and economic outcomes
    • Lautenbach E, Weiner MG, Nachamkin I, et al. Imipenem resistance among Pseudomonas aeruginosa isolates: Risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006;27:893-900.
    • (2006) Infect. Control Hosp. Epidemiol , vol.27 , pp. 893-900
    • Lautenbach, E.1    Weiner, M.G.2    Nachamkin, I.3
  • 18
    • 77957587068 scopus 로고    scopus 로고
    • Period Life Table, Available at, Accessed August 20, 2008
    • US Social Security Administration. Period Life Table, 2004. Available at http://www.ssa.gov/OACT/STATS/table4c6.html. Accessed August 20, 2008.
    • (2004) US Social Security Administration
  • 19
    • 1642451852 scopus 로고    scopus 로고
    • Linezolid for treatment of ventilator-associated pneumonia: A cost-effective alternative to vancomycin
    • Shorr AF, Susla GM, Kollef MH. Linezolid for treatment of ventilator-associated pneumonia: A cost-effective alternative to vancomycin. Crit Care Med 2004;32:137-143.
    • (2004) Crit. Care Med. , vol.32 , pp. 137-143
    • Shorr, A.F.1    Susla, G.M.2    Kollef, M.H.3
  • 20
    • 0031003777 scopus 로고    scopus 로고
    • Magnitude and duration of the effect of sepsis on survival
    • Quartin AA, Schein RM, Kett DH, et al. Magnitude and duration of the effect of sepsis on survival. JAMA 1997;277:1058-1063.
    • (1997) JAMA , vol.277 , pp. 1058-1063
    • Quartin, A.A.1    Schein, R.M.2    Kett, D.H.3
  • 21
    • 0034561810 scopus 로고    scopus 로고
    • Outcomes and costeffectiveness of ventilator support and aggressive care for patients with acute respiratory failure due to pneumonia or acute respiratory distress syndrome
    • Hamel MB, Phillips RS, Davis RB, et al. Outcomes and costeffectiveness of ventilator support and aggressive care for patients with acute respiratory failure due to pneumonia or acute respiratory distress syndrome. Am J Med 2000;109:614-620.
    • (2000) Am. J. Med. , vol.109 , pp. 614-620
    • Hamel, M.B.1    Phillips, R.S.2    Davis, R.B.3
  • 22
    • 84877495647 scopus 로고    scopus 로고
    • Consumer Price Index. Available at, Accessed August 20, 2008
    • US Bureau of Labor Statistics. Consumer Price Index. Available at http://www.bls.gov. Accessed August 20, 2008.
    • US Bureau of Labor Statistics
  • 23
    • 84858006048 scopus 로고    scopus 로고
    • Available at, Accessed September 3, 2008
    • Institute for Healthcare Improvement. Available at http://www.ihi.org. Accessed September 3, 2008.
    • Institute for Healthcare Improvement
  • 25
    • 77957586218 scopus 로고    scopus 로고
    • U. S. Government, 527-23, 576. Available at, DOCID: fr30ap08-26. Accessed May 8, 2008
    • U. S. Government. Proposed Rules. Fed Reg 2008;73:23, 527-23, 576. Available at http://wais.access.gpo.gov [DOCID: fr30ap08-26]. Accessed May 8, 2008.
    • (2008) Proposed Rules. Fed Reg , vol.73 , pp. 23
  • 26
    • 3342905057 scopus 로고    scopus 로고
    • Doripenem versus Pseudomonas aeruginosa in vitro: Activity against characterized isolates, mutants, and transconjugants and resistance selection potential
    • Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: Activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004;48:3086-3092.
    • (2004) Antimicrob. Agents Chemother. , vol.48 , pp. 3086-3092
    • Mushtaq, S.1    Ge, Y.2    Livermore, D.M.3
  • 27
    • 33744950954 scopus 로고    scopus 로고
    • Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: The high potency of a new carbapenem doripenem
    • Sakyo S, Tomita H, Tanimoto K, et al. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: The high potency of a new carbapenem doripenem. J Antibiot 2006;59:220-228.
    • (2006) J. Antibiot , vol.59 , pp. 220-228
    • Sakyo, S.1    Tomita, H.2    Tanimoto, K.3
  • 28
    • 70350397040 scopus 로고    scopus 로고
    • Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa
    • Shigemi A, Matsumoto K, Yaji K, et al. Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents 2009;34:589-591.
    • (2009) Int. J. Antimicrob. Agents , vol.34 , pp. 589-591
    • Shigemi, A.1    Matsumoto, K.2    Yaji, K.3
  • 29
    • 0037253093 scopus 로고    scopus 로고
    • Costeffectiveness of drotrecofin alfa (activated) in the treatment of sepsis
    • Angus DC, Linde-Zwirble WT, Clermont G, et al. Costeffectiveness of drotrecofin alfa (activated) in the treatment of sepsis. Crit Care Med 2003;31:1-11.
    • (2003) Crit. Care Med. , vol.31 , pp. 1-11
    • Angus, D.C.1    Linde-Zwirble, W.T.2    Clermont, G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.